Liaocheng

Researchers are evaluating the effectiveness and safety of Yangxinshi tablets for patients with chronic coronary syndrome (CCS) in a prospective, multicenter, randomized, open-label, blinded-endpoint phase 4 clinical trial. The study aims to improve exercise capacity measured by the 6-minute walking distance (6MWD) in CCS patients who have stable disease and limited exercise tolerance. The trial will enroll 1200 patients with CCS, randomly assigned in a 3:1 ratio to either the experimental group or the control group. The experimental group will receive Yangxinshi tablets (three tablets, three times daily) in addition to their basic medication, while the control group will continue with basic medication only. The treatment period lasts 24 weeks. Participants will be assessed primarily by measuring their 6MWD after 24 weeks of treatment. The study includes stable CCS patients diagnosed by coronary artery imaging with at least one vessel stenosis of 50% or more. Exercise tolerance will be evaluated by treadmill cardiopulmonary exercise testing or the 6-minute walk test. Safety and efficacy will be monitored throughout the study period.